Amneal Pharmaceuticals Reaps $2.5M in Kentucky Incentives
05/11/2010
"In addition to compelling economic incentives, we recognized that the superb quality and dedication of Glasgow's work force is a key factor in Amneal's reputation for service excellence, so the decision to stay and expand operations in Kentucky was an easy one," said Jim Luce, Amneal executive vice president of sales and marketing.
The Kentucky Economic Development Finance Authority has pre-approved Amneal for tax incentives up to $2.5 million through the Kentucky Business Investment program.
Amneal plans to use the funds to consolidate distribution logistics and sales in a 115,000-square-foot Glasgow facility. It will combine distribution that currently exists in Long Island, New York and Fountain Run, Kentucky. The company develops, manufactures, and distributes generic pharmaceuticals. It is the tenth largest supplier of generic drugs in the country in terms of prescriptions dispensed.
Project Announcements
Riverstone Logistics Plans Rock Hill, South Carolina, Headquarters-Production Operations
09/20/2025
Swiss-Based ABB Expands Henrico County, Virginia, Operations
09/19/2025
Eli Lilly and Company Plans Goochland County, Virginia, Specialty Pharmaceutical Operations
09/19/2025
India-based Biocon Limited Establishes Cranbury, New Jersey, Production Operations
09/19/2025
India-Based Enzene Biosciences Establishes Hopewell, New Jersey, Manufacturing Operations
09/17/2025
Ring Container Technologies Plans Whitestown, Indiana, Operations
09/17/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025